- Home
- FI vs GILD Comparison
FI vs GILD Comparison
Compare FI & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FI
- GILD
- Stock Information
- Founded
- FI 1984
- GILD 1987
- Country
- FI United States
- GILD United States
- Employees
- FI N/A
- GILD N/A
- Industry
- FI Business Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FI Consumer Discretionary
- GILD Health Care
- Exchange
- FI Nasdaq
- GILD Nasdaq
- Market Cap
- FI 124.0B
- GILD 113.0B
- IPO Year
- FI 1986
- GILD 1992
- Fundamental
- Price
- FI $206.09
- GILD $92.57
- Analyst Decision
- FI Buy
- GILD Buy
- Analyst Count
- FI 25
- GILD 26
- Target Price
- FI $219.92
- GILD $96.71
- AVG Volume (30 Days)
- FI 3.2M
- GILD 6.7M
- Earning Date
- FI 02-04-2025
- GILD 02-11-2025
- Dividend Yield
- FI N/A
- GILD 3.33%
- EPS Growth
- FI 8.67
- GILD N/A
- EPS
- FI 5.19
- GILD 0.10
- Revenue
- FI $20,122,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- FI $3.48
- GILD $6.50
- Revenue Next Year
- FI $8.47
- GILD $0.36
- P/E Ratio
- FI $39.70
- GILD $953.26
- Revenue Growth
- FI 6.99
- GILD 3.31
- 52 Week Low
- FI $131.41
- GILD $62.07
- 52 Week High
- FI $223.23
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- FI 48.22
- GILD 54.42
- Support Level
- FI $201.61
- GILD $90.27
- Resistance Level
- FI $208.28
- GILD $93.59
- Average True Range (ATR)
- FI 4.01
- GILD 2.19
- MACD
- FI -1.08
- GILD -0.17
- Stochastic Oscillator
- FI 28.40
- GILD 62.18
About FI Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).